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Abstract 
Background: Vivax malaria occurring in the Republic of Korea is occasionally characterized by a long latent infection 
induced by hypnozoites in the liver. So far, the mechanisms responsible for short and long latent infections of vivax 
malaria are not known. Therefore, the present study classified the parasite isolates according to the long and short 
latent periods and then analysed the genetic diversity of the Plasmodium vivax merozoite surface protein 1 (PvMSP‑1).
Methods: Blood samples containing P. vivax isolates were collected from 465 patients from 2011 to 2013 at health 
centers in the Republic of Korea. PvMSP‑1 gene sequences were analysed in groups classified by the collection year, 
and short or long latent periods. The samples in short and long latent periods were selected by the timing of vivax 
malaria occurrence, July–August and January–May, respectively.
Results: Three PvMSP‑1 types (Sal‑1, Belem, and recombinant) were observed in P. vivax isolates collected from 2011 
to 2013. Interestingly, the recombinant and Sal‑1 types were dominant in vivax malaria of the long and short latent 
periods, respectively. In addition, the S‑b like subtype of the PvMSP‑1 Sal‑1 type was first identified in 2013.
Conclusion: This study revealed that the genetic type of PvMSP‑1 is likely related to the duration of its latent period. 
Moreover, trends of the genetic types of PvMSP‑1 seem to be stable in recent years compared with those of previous 
years in which various new types were observed.
© 2015 Goo et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Vivax malaria caused by Plasmodium vivax is the most 
prevalent form of human malaria and afflicts several hun-
dred million people annually [1]. It is endemic in tropi-
cal and subtropical countries of Africa, the Middle East, 
the South Pacific, Central and South America, and Asia, 
including the Republic of Korea (ROK) [2]. In the ROK, 
P. vivax infection was highly endemic and considered an 
indigenous disease by the late 1970s. Subsequently, vivax 
malaria was eradicated by efforts of the World Health 
Organization and the National Malaria Eradication Pro-
gramme, until the disease was found in a soldier serving 
in the demilitarized zone (DMZ) between the ROK and 
the Democratic People’s Republic of Korea (DPRK) in 
1993 [3, 4]. Since then, the number of vivax malaria cases 
reached more than 4,000 cases in 2000, decreased again 
to less than 500 cases in 2013, and increased to approxi-
mately 670 cases in 2014 [5]. The occurrence of vivax 
malaria is concentrated in regions close to the DMZ; 
thus, it has been suggested that the outbreaks of vivax 
malaria in the ROK and the DPRK are correlated [6, 7].
Vivax malaria transmission in the ROK is unstable and 
seasonal, peaking in July and August because the cli-
mate is temperate [8, 9]. Compared to Plasmodium fal-
ciparum, P. vivax infection is characterized by a relapse 
Open Access
*Correspondence:  jykim‑malaria@nih.go.kr 
1 Division of Malaria and Parasitic Diseases, National Institute of Health, 
Korea CDC, Osong Saeng‑myeong 2 ro, Osong Health Technology 
Administration, Osong, Republic of Korea
Full list of author information is available at the end of the article
Page 2 of 6Goo et al. Malar J  (2015) 14:299 
caused by a hypnozoite in the human liver [10, 11]. After 
transmission via a bite from a P. vivax-infected mos-
quito, sporozoites generally develop into schizonts that 
result in the primary illness. However, some sporozoites 
enter hepatocytes and then develop into hypnozoites in 
the human liver [12, 13]. The hypnozoites can become 
active months or even years later, leading to a relapse 
of vivax malaria after resolution of the primary illness 
[14]. The mechanisms responsible for the development 
of the hypnozoite stage and the subsequent relapse of 
the disease are still unknown. In addition, the presence 
of hypnozoites results in a prolonged incubation period 
of vivax malaria referred to as a long latent period, while 
vivax malaria parasites generally lead to primary illness 
after a short latent period (within several days after a 
vivax malaria-infected mosquito bite) [15]. Although the 
occurrence of vivax malaria in the ROK is seasonal in 
July–August (summer season), a few cases are reported 
during winter season as a result of parasites with long 
latent period.
Genotyping studies have been used to gain a better 
understanding of the population structure of patho-
gens, including the Plasmodium species, and to develop 
an effective vaccine against these parasites [16–18]. The 
population structure of certain genes could explain the 
transmission dynamics and evolutionary trend of the 
Plasmodium species. Moreover, genetic diversity of vac-
cine candidates has been investigated because the exten-
sive genetic diversity within natural malaria parasite 
populations has hampered efforts to develop an effec-
tive vaccine [19, 20]. Merozoite surface protein 1 of P. 
vivax (PvMSP-1) is a well-known vaccine candidate as 
well as a marker for genotyping [21–23]. PvMSP-1 is 
composed of several variable blocks flanked by 10 con-
served regions containing a dimorphic pattern. Block 5 is 
located between two of the interspecies conserved blocks 
(ICBs), ICB5 and ICB6, and shows a dimorphic pattern of 
sequences with little homology. The first two isolates of 
polymorphic PvMSP-1 were identified in Latin America 
and named the Brazilian Belem (Belem) and Salvador 
(Sal-1) strains [24, 25]. Shortly after, the mosaic organiza-
tion and heterogeneity in the frequency of allelic recom-
bination of PvMSP-1 were demonstrated in P. vivax 
isolates from different countries [26]. The results of these 
analyses of PvMSP-1 polymorphisms have enhanced the 
data collected from epidemiological and molecular bio-
logical surveys.
In the present study, the sequences of PvMSP-1 in P. 
vivax isolates collected from 2011 to 2013 in the ROK 
were analysed. The sequence data were evaluated to 
understand the genetic diversity of the recent P. vivax 
population in the ROK in comparison with that of pre-
viously studied populations [27, 28]. In addition, the 
genotypes of vivax malaria parasites involved in the long 
and short latent periods were analysed.
Methods
Ethics
The study was approved by the ethics committee of the 
Korea National Institute of Health. An approval form 
was used to obtain written informed consent from each 
participant. Each participant also consented to provide a 
5-mL blood sample.
Sample collection
Venous blood samples preserved with EDTA were 
received from 465 patients diagnosed with vivax malaria 
at local health centers and hospitals from 2011 to 2013. 
Eighty-five, 248, and 132 samples were collected in 2011, 
2012, and 2013, respectively. Microscopic examination of 
Giemsa-stained thick and thin blood films was used to 
confirm the diagnosis. Blood specimens were kept cool 
and arrived at the Korea Centers for Disease Control and 
Prevention (KCDC) within 24  h after collection. Long 
or short latent period groups were classified using an 
arbitrary definition according to the date of the patient’s 
visit to the hospital with malaria symptoms. The short 
and long latent periods of vivax malaria were defined as 
a hospital visit date in July–August and January–May, 
respectively.
DNA extraction
Genomic DNA of P. vivax was extracted from 200 μL of 
each blood sample using a QIAamp DNA Mini Kit (Qia-
gen, USA) following the manufacturer’s instructions.
PCR amplification and sequencing of PvMSP‑1
The sequence between ICBs 5 and 6 of MSP-1 of P. vivax 
was amplified as previously described [27]. Primers used 
for the amplification were MSP1A (5′-GAGCCCTACTA 
CTTGATGGTCC-3′) and MSP1B (5′-CCTTCTGGTACA 
GCTCAATG-3′). Amplification was performed in a 
20-μL reaction mixture containing the genomic DNA 
of P. vivax, 1 × reaction buffer, 2.5 mM MgCl2, 0.2 mM 
of each dNTP, 10 pmol of each primer, and 1 unit of Ex 
Taq DNA polymerase (Takara, Japan). PCR cycling con-
ditions included an initial denaturation at 95°C for 7 min; 
followed by 35 cycles of denaturation at 94°C for 1 min, 
annealing at 58°C for 1  min, and extension at 72°C for 
1 min; and a final extension at 72°C for 7 min. The PCR 
products were subjected to electrophoresis on a 1% aga-
rose gel.
Purification of PCR products and sequencing of PvMSP‑1
The PCR products were purified using a QIAquick 
Gel Extraction kit (Qiagen, USA) according to the 
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manufacturer’s instructions. After gel purification, the 
PCR products were sequenced with the primers from 
ICB5–ICB6 using an ABI 3730XL DNA Analyzer auto-
mated sequencer (Applied Biosystems, USA).
Sequence analysis
Parasite gene sequences obtained from the blood samples 
of the malaria patients in this study were compared with 
previously published PvMSP-1 gene sequences. CLC 
Sequence Viewer 6.8.1 (CLC bio, USA) was used to con-
vert nucleotide sequences into amino acid sequences and 
to align the sequences.
Statistical analysis
Any statistically significant differences were determined 
by Student’s t test using JMP Version 8 (SAS Institute 
Inc., USA). P  <  0.05 was considered to be statistically 
significant.
Results
The polymorphisms within block 5 of PvMSP1 were 
analysed from 465 isolates collected from 2011 to 2013. 
Three PvMSP-1 types (Sal-1, Belem, and recombinant 
types) have been found previously in Korean vivax iso-
lates. Since 2003, the majority of isolates have belonged 
to the Sal-1 type; however, the proportion of Sal-1 iso-
lates has been decreasing each year since 2011 (Fig. 1). 
As shown in Table 1, the percentage of Sal-1 isolates in 
each year was 52.9% (2011), 42.7% (2012), and 39.4% 
(2013). Since 2004, both the S-a and S-b subtype iso-
lates have coexisted in the ROK. Recently, isolates of 
the S-b subtype of Sal-1 were found to have decreased 
from 24.7% in 2011 to 15.2% in 2013, while the S-a sub-
type showed a similar decrease in proportion among P. 
vivax isolates (28.2% in 2011, 24.2% in both 2012 and 
2013). Interestingly, one isolate of the S-b type harbored 
a mutation that changed a glycine residue to a glutamic 
acid residue at position 725 (p.G725E). Thus, this isolate 
was named as the S-b like subtype. In comparison with 
Sal-1 type isolates, the number of PvMSP-1 Belem type 
isolates has been increasing from 2011 to 2013. All iso-
lates of the Belem type were of the B-1 subtype. The per-
centage of PvMSP-1 recombinant type isolates in 2012 
(37.1%) and 2013 (36.4%) was increased compared to 
that seen in 2011 (28.2%). Although the R2, R3, and R4 
subtypes of the PvMSP-1 recombinant type were found 
in 2010, these subtypes did not appear from 2011 to 
2013. During the three-year period, only the R1 subtype 
was observed.
Each sample was subsequently classified into long or 
short latent period groups according to the date of the 
patient’s visit to the hospital with malaria symptoms. 
The short and long latent periods of vivax malaria were 
defined by a hospital visit date in July–August and Janu-
ary–May, respectively. Of the original 465 samples, 226 
were selected for the short latent period of vivax malaria: 
Fig. 1 Frequency of Plasmodium vivax merozoite surface protein 1 (PvMSP‑1) strains in the ROK during the previous (1996–2010) and current 
(2011–2013) study periods. No spot regions indicate only one subtype (S‑b, B‑1, and R‑1) without variation; single open circle S‑a subtype, double 
open circle S‑a and S‑c subtypes, triple open circle S‑b like subtype, single filled circle B‑2 subtype, double filled circle R2, R3, and R4 subtypes.
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24 from 2011, 145 from 2012, and 57 from 2013. There 
were 58 total samples from the long latent period from 
2011 (n  =  13), 2012 (n  =  21), and 2013 (n  =  24). The 
PvMSP-1 types in both periods showed the same pat-
tern in each year: the MSP-1 recombinant type was sig-
nificantly predominant in the long latent period samples 
(P < 0.05), while the MSP-1 Sal-1 type was most prevalent 
in the short latent period samples (P < 0.05). As shown 
in Fig.  2, the PvMSP-1 recombinant type accounted 
for 46.2% (2011), 52.4% (2012), and 50.0% (2013) of the 
long latent period isolates (January-May), but only 37.5, 
34.5, and 33.3% of the short latent period samples (July–
August) from each respective year. However, the propor-
tions of the PvMSP-1 Sal-1 type, 38.4% in 2011, 28.6% in 
2012, and 33.3% in 2013, in the long latent period isolates 
were increased to 54.2, 46.2, and 40.4% in the short latent 
period isolates of each respective year (Fig. 2).
Discussion
In the current study, the genetic diversity of the P. 
vivax merozoite surface protein 1 gene was investi-
gated in field isolates from vivax malaria patients in a 
high transmission area of the Republic of Korea (ROK) 
as a continuation of two previous reports [27, 28]. In 
order to compare the genetic structure of the ROK iso-
lates, sequences from Block 5 were analysed, a vari-
able region of PvMSP-1. After the PvMSP-1 Sal-1 type 
and Belem type were first reported in 2000 and 2003, 
respectively, all three strains of P. vivax (Sal-1, Belem, 
and recombinant types) were found in 2011–2013. Inter-
estingly, a PvMSP-1 S-b like type, containing p.G725E, 
which changes glycine to glutamic acid, was found in 
an isolate collected in 2013. It seems likely that genetic 
recombination resulting in a single nucleotide polymor-
phism (SNP) occurred in the PvMSP-1 gene, because 
PvMSP-1 is a highly polymorphic antigen [29]. Moreo-
ver, the P. vivax recombinant type increased in the later 
years (2012 and 2013) compared with 2011, which is 
likely a result of genetic recombination or a crossing of 
P. vivax Sal-1 and Belem types. However, co-infection of 
PvMSP-1 Sal-1 and Belem types in a single sample was 
not observed, which could have indicated the possibil-
ity of crossing of the P. vivax types. That might be due 
to the fact this genotyping that used simple PCR meth-
ods and followed sequencing analysis tends to amplify 
only the dominant type. Therefore, further polyclonal 
Table 1 PvMSP-1 block 5 allelic subtype frequencies of  P. 
vivax isolates from the Republic of Korea
Year No. of samples (%)
Recombinant Belem Sal‑1 Total
B‑1 S‑a S‑b
2011 24 (28.2) 16 (18.9) 24 (28.2) 21 (24.7) 85
2012 92 (37.1) 50 (20.2) 60 (24.2) 46 (18.5) 248
2013 48 (36.4) 32 (24.2) 32 (24.2) 20 (15.2) 132
Fig. 2 Frequency of Plasmodium vivax merozoite surface protein 1 (PvMSP‑1) strains in the ROK in the long (January–May) and short (July–August) 
latent periods from 2011 to 2013. *significant difference (P < 0.05) in the PvMSP‑1 recombinant type proportion between long and short latent 
periods; **significant difference (P < 0.05) in the PvMSP‑1 Sal‑1 type proportion between long and short latent periods.
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infection studies should be done using microsatellite or 
pyrosequencing analysis, which are known to be capa-
ble of identifying mixed infections. In addition, only the 
original PvMSP-1 recombinant type (10×Q) appeared 
during the three-year period (2011–2013), whereas high 
levels of polymorphism in the number of Q repeats were 
observed in 2010 (12×Q, 14×Q, and 27×Q). Although 
the regions of sample collection were the same, the new 
subtypes with different numbers of Q residue repeats 
were not observed during the recent sample collection 
period. This indicates that the 12×Q, 14×Q, and 27×Q 
subtypes did not become established and subsequently 
disappeared from the P. vivax population of the ROK, 
like the S-c and B-2 subtypes only in 2003 and 2006, 
respectively. This also suggests that transmission might 
not be dynamic in the ROK. This finding was supported 
by a microsatellite study of ROK isolates suggesting con-
tinuous introduction of P. vivax variants into the ROK 
from other parasite population sources, especially from 
DPRK [30, 31].
Vivax malaria in the ROK is characterized by a long 
latent infection. The incubation period of a primary 
infection of vivax malaria is 7–30  days; however, in the 
ROK, the disease sometimes does not show an onset of 
symptoms until several months after the initial infection 
by mosquito bites [32]. Therefore, in the present study, 
samples were divided into short (July–August) and long 
(January–May) latent periods using an arbitrary defini-
tion. And then, P. vivax isolates were analysed in order 
to determine the dominant strains involved in both the 
short and long latent periods of vivax malaria. To date, 
the major P. vivax strains inducing the short or long 
latent periods of vivax malaria have not been investi-
gated. This study, using field isolates of the short and 
long latent periods, showed that P. vivax of the PvMSP-1 
recombinant type was dominant in the long latent period 
isolates. This finding was consistent over three successive 
years (2011–2013). Based on this result, it is likely that 
this specific P. vivax strain easily induces long latency 
and the development of the hypnozoite. However, further 
broad surveillance studies would be necessary in order to 
verify this finding.
The merozoite surface protein 1 is one of the most stud-
ied vaccine candidates of vivax malaria. High genetic pol-
ymorphism within PvMSP-1 has been reported in other 
countries. In addition, the genetic diversity has increased 
over the past decade from two genotypes to six found in 
the ROK. This allelic polymorphism is one of the great-
est hurdles to inducing a protective immune response 
against the genetically diverse P. vivax because amino 
acid variations can affect the immunogenic properties of 
antigens. Therefore, continuous research will be neces-
sary to determine the impact of antigenic diversification 
on the immunogenicity of the PvMSP-1 antigen in natu-
ral populations.
Conclusion
Sequence analysis of Block 5 of PvMSP-1 identified the 
Sal-1 (S-a and S-b subtypes), Belem (B-1 subtype), and 
recombinant types in Plasmodium vivax isolates col-
lected from the Republic of Korea from 2011 to 2013. The 
trends of the genetic types of PvMSP-1 seem to be con-
sistent with previous years, except for the appearance in 
2013 of an S-b like subtype of the Sal-1 type containing 
one SNP. Interestingly, the PvMSP-1 recombinant type 
and the Sal-1 type were the predominant types observed 
in P. vivax isolates in the long and short latent periods, 
respectively.
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